Moxibac IV Infusion 400 mg/250 ml

Moxibac is a potent antibiotic injection manufactured by Popular Pharmaceuticals Ltd. Containing Moxifloxacin Hydrochloride 400 mg/250 ml, this IV Infusion formulation effectively treats bacterial infections in adults. Priced at ৳350.00 per unit, it requires storage below 25°C with light protection.

Prescribed for respiratory infections, skin disorders, and intra-abdominal complications, Moxibac works by inhibiting bacterial DNA replication. Its once-daily 400 mg dosage simplifies treatment regimens. Clinical studies show efficacy against pneumonia, sinusitis, and cellulitis.

Key indications include:

• Acute bacterial sinusitis (10-day course)
• Community-acquired pneumonia (7-14 days)
• Complicated skin infections (7-21 days)

Notable drug interactions occur with antacids, warfarin, and NSAIDs. Common side effects (<1%) include nausea and headache. Serious risks involve QT prolongation - avoid concurrent use with antiarrhythmics. Category C pregnancy status warrants cautious use.

This IV Infusion requires professional administration. Patients should complete the full course despite symptom improvement. Monitor blood glucose levels in diabetics due to potential fluctuations.

400mg once daily via IV infusion over 60 minutes. Sinusitis: 10 days, Bronchitis: 5 days, Pneumonia: 7-14 days. No renal dose adjustment needed. Administer as slow IV infusion. Use shortest effective duration to prevent resistance.

Treatment with Moxibac (oral, IV or sequential therapy) may cause some side effects. Common (>1%) side effects include headache, nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dizziness, pyrexia and insomnia etc. Less common (0.1 to <1%) side effects include neutropenia, palpitations, tachycardia, bradycardia, vertigo, tinnitus, dry mouth, gastritis, edema, fatigue, malaise, hyperglycemia, anorexia, hyperlipidemia, hypoglycemia, dehydration, back pain and arthralgia etc.

Pregnancy Category C: Risk not established. Avoid during lactation. Use only if potential benefit justifies fetal risk. Discontinue breastfeeding during treatment.

Monitor tendon pain in elderly >60 years. Caution in epilepsy patients – seizure risk. Maintain hydration to prevent crystalluria. Report IV site reactions immediately. Regular liver function tests in prolonged therapy.

Pediatric: Not approved <18 years. Geriatric: Increased tendon/renal risks. Renal impairment: No dose adjustment. Hepatic impairment: Caution in severe cirrhosis.